HOME >> MEDICINE >> NEWS
Bacterial DNA reduces inflammation in mice

DNA from inactivated "probiotic" bacteria triggers a specific anti-inflammation immune response in mice with experimental colitis, researchers supported by the NIH's National Institute of Allergy and Infectious Diseases (NIAID) have discovered. Led by Eyal Raz, M.D., of the University of California, San Diego (UCSD), the investigators provide a possible explanation for the observed benefits of consuming probiotics, supplements from bacteria and other microbes, regarded by some as helpful in maintaining or restoring intestinal health. Knowing how probiotics work could give scientists a way to identify and select which probiotic bacteria might be effective against such human ailments as inflammatory bowel disease (IBD).

Probiotics have shown promise for treating such IBDs as Crohn's disease and ulcerative colitis, both of which cause periodic intestinal inflammation. But scientists have had many theories of how these mixtures of "good" bacteria work, notes Marshall Plaut, M.D., of NIAID's Division of Allergy, Immunology and Transplantation. Plausible theories suggested that proliferation of the living bacteria either generated helpful metabolic products or crowded out "bad" intestinal bugs. Prior to this study, the general thinking about probiotics, which include bacteria like those found in yogurt, has been that they mediate their effects through some kind of non-specific action, adds Dr. Plaut.

Dr. Raz and his colleagues, whose work is published in the February 2004 issue of the journal Gastroenterology, irradiated a commercially available probiotic preparation, halting bacterial proliferation, but preserving its DNA. When given to mice, the irradiated probiotics performed as well as live bacteria in reducing inflammation. They also found that purified probiotic bacterial DNA alone similarly reduces inflammation in mice with experimentally induced colitis.

The researchers also showed that probiotic DNA acts in a specific way by activating
'"/>

Contact: Anne A. Oplinger
aoplinger@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
2-Feb-2004


Page: 1 2

Related medicine news :

1. Bacterial infection may cause or worsen asthma attacks in children
2. Bacterial protein kills tumors
3. Bacterial vaginosis seems to affect miscarriage in early pregnancy
4. Geodon effective in psychiatric emergencies; Sharply reduces time in restraints
5. Targeting mutant B-Raf protein reduces melanoma development
6. Rasagiline reduces disability for patients with advanced Parkinsons disease
7. Breast cancer treatment reduces risk of heart disease
8. Carrot component reduces cancer risk
9. Sex hormone metabolite reduces stress, anxiety in female rats
10. Sunlight reduces risk of lymph gland cancer
11. Male circumcision reduces risk of HIV transmission from women to men

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Bacterial DNA reduces inflammation mice

(Date:5/22/2015)... The world is at a "hinge ... to create new opportunities for leadership in health ... WesternU's 34th annual Commencement Exercises said Wednesday, May ... former San Francisco mayor and likely 2018 gubernatorial ... ceremony for WesternU's colleges of Allied Health Professions ...
(Date:5/22/2015)... The American College of Traditional Chinese Medicine ... will hold a webinar on the updates of the ... Classical Chinese Medicine. , Webinar – First Professional Doctorate ... Dean of Clinical Education, will lead this webinar in ... program. ACTCM is currently developing this degree program based ...
(Date:5/22/2015)... River Valley Health Partners (RVHP) Board ... system’s Chief Financial Officer (CFO), will be leaving the ... the company CFO since 2011. , The Board of ... health system as CFO. Wesley will oversee the health ... Board of Trustees conducts a formal search for a ...
(Date:5/22/2015)... Following yesterday’s announcement that Ascenta Health Limited ... brand Nature’s Way, Marc St-Onge has affirmed his commitment ... is an integral part of the agreement with Nature’s ... further develop Ascenta Skin into a leading player in ... breakthrough, anti-aging skincare supplement featuring 6 active ingredients including ...
(Date:5/22/2015)... UK (PRWEB) May 22, 2015 ... leading treatment option for chronic obstructive pulmonary disorder ... GlaxoSmithKline plc and AstraZeneca plc as well as ... market share and position. But will market payers, ... the already well-entrenched products to completely new ones? ...
Breaking Medicine News(10 mins):Health News:Newsom to WesternU Grads: The Future is Inside You 2Health News:Newsom to WesternU Grads: The Future is Inside You 3Health News:ACTCM Announces Upcoming June Events 2Health News:River Valley Health Partners Announces CFO Transition, Appointment of Interim CFO 2Health News:Ascenta Skin President Announces Plans to Grow Brand 2Health News:Chronic Obstructive Pulmonary Disorder Therapeutics Market Discussed in In-demand FirstWord Report Published at MarketPublishers.com 2
(Date:5/22/2015)...  BioLife Solutions, Inc. (NASDAQ: BLFS ), a leading ... storage and cryopreservation freeze media and ... or the "Company"), announced that the Company is scheduled to ... The Company is scheduled to present at the Conference at ... Grand Hyatt Hotel in New York City ...
(Date:5/22/2015)... , May 22, 2015 The ... the $13 billion global cardiac rhythm management device ... Kalorama found that Medtronic, St. Jude Medical, Boston ... 80% of this market segment. The healthcare market ... Markets , uses 2015 as a base year, ...
(Date:5/22/2015)... , May 22, 2015  The U.S. Food ... (filgrastim-sndz) -- the first biosimilar product approved in ... points toward growth in the contract manufacturing organization ... CMO industry is geared to the production of ... major biopharmaceutical products. The healthcare market research publisher,s ...
Breaking Medicine Technology:BioLife Solutions To Present At The 2015 Marcum MicroCap Conference In New York City 2Kalorama: Top Companies Dominate Cardiac Defibrillator Market 2Kalorama: Top Companies Dominate Cardiac Defibrillator Market 3Kalorama: Top Companies Dominate Cardiac Defibrillator Market 4Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 2Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 3Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 4
Cached News: